From the press release:

IGI, INC. announced that it has received, a Small Business Technology Transfer (STTR) grant from the National Cancer Institute to evaluate the safety and therapeutic potential of parathyroid hormone PTH (7-34) analog to treat alopecia induced by chemotherapy in breast cancer patients.

In previous animal testing, IGI “successfully formulated PTH 7-34 into its proprietary Novasome encapsulation technology, and the treatment both stimulated and maintained hair growth in mice. This next round of testing will be performed on human subjects under the oversight of Dr. Michael Holick at Boston University.

Post from: Blisstree

IGI Receives National Cancer Institute Grant

Here’s the point of relevence, from the press release:

IGI is also exploring the licensing of the topical PTH (7-34) compound for the prevention/treatment of chemotherapy induced-alopecia in patients undergoing chemotherapy.

PTH, that is parathyroid hormone, therapies may have the ability to reduce or reverse chemotherapy induced baldness. Or at least I’m pretty sure that’s what this article from the National Library of Medicine says.

Post from: Blisstree

Possible PTH Based Treatments for Chemotherapy Induced Baldness